SCHEMBL6763294

SCHEMBL6763294

C=CCNS(=O)(=O)c1ccc(Cl)c(C)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 2/20 0.44
WDR5 P61964 1/20 0.43
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
PDK3 Q15120 1/20 0.40
PDK4 Q16654 1/20 0.40
ALDH1A1 P00352 4/20 0.40
POLB P06746 2/20 0.38
PKM P14618 1/20 0.37
LMNA P02545 3/20 0.37
KMT2A Q03164 2/20 0.37
MITF O75030 1/20 0.37
NSD2 O96028 1/20 0.37
CASP3 P42574 1/20 0.37
HTT P42858 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119703 0.79 WDR5 (0.47) WDR5ALDH1A1POLBPKMLMNA
SCHEMBL5119706 0.79 WDR5 (0.47) WDR5ALDH1A1POLBPKMLMNA
SCHEMBL6766636 0.77 ALDH1A1 (0.45) SMN1; SMN2GAAWDR5TSHRALDH1A1
SCHEMBL4030951 0.75 WDR5 (0.50) SMN1; SMN2GAAWDR5TSHRALDH1A1
SCHEMBL4029646 0.75 WDR5 (0.48) GAAWDR5ALDH1A1POLBPKM
SCHEMBL6761723 0.74 WDR5 (0.47) WDR5ALDH1A1POLBPKM
SCHEMBL4030663 0.72 WDR5 (0.46) GAAWDR5ALDH1A1POLBLMNA
SCHEMBL4029240 0.72 ALDH1A1 (0.54) SMN1; SMN2GAAMAPK1ALDH1A1POLB
SCHEMBL4033630 0.72 WDR5 (0.48) SMN1; SMN2WDR5MAPK1ALDH1A1POLB
SCHEMBL4070788 0.71 TSHR (0.49) SMN1; SMN2TSHRMAPK1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB SMN1; SMN2 398/4885GAA 492/4885WDR5 4094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.